APOGEE THERAPEUTICS INC (APGE)
Health Care · biotechnology · NASDAQ
Apogee Therapeutics is a clinical-stage biotechnology firm developing advanced biologic therapies for inflammatory and immunology diseases, currently pending acquisition by AbbVie.
What APOGEE THERAPEUTICS INC does
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologic product candidates for the treatment of inflammatory and immunology conditions. Its development programs target high unmet needs in diseases including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. The company is currently a party to a pending acquisition agreement with AbbVie.
Themes: immunology, inflammatory diseases, biologics, mergers and acquisitions
Fundamentals
- Price$135.07 last close before the listing ended, 2026-09-04
- Market cap$10.2B as of 2026-06-30 (share count; price 2026-09-04)
- 1-year return+263.8% 2025-09-04 close $37.13 → 2026-09-04 close $135.07
- P/En/a negative earnings
- ROE-28.3% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta1.16 as of 2026-09-03
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
This listing has ended. The figures below are the last on record, from 2026-09-04, not a current quote.
How APGE compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Analyst consensus
- Consensus ratingHold (2.71 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$134.62 range $133.00 – $135.11; median $135.00
Analyst estimates, as of 2026-09-14. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for APGE
- Consensus EPS estimate-$1.25 next reporting period, as of 2026-09-14
- Readings revised upward0% of 4 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Failure to complete the pending merger with AbbVie due to regulatory or closing conditions.","Risks associated with the clinical-stage nature of product candidates and the uncertainty of regulatory approval.","High dependence on third parties for clinical trial conduct and drug manufacturing."]
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($737935) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 20 sells ($23M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-05. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about APGE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding APGE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 16,163,508
- Reported value $1,360,482,386
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about APGE's institutional holders → See what each manager we track holds →
Short interest (FINRA)
APGE had 4,203,052 shares of reported short interest as of the 2026-08-31 FINRA settlement date (delayed, bi-monthly; not real-time).
APGE had 5.58% of its shares outstanding sold short as of the 2026-08-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.47 days to cover at the same settlement.
- Reported short interest (shares) 4,203,052
- Short interest (% of shares outstanding) 5.58%
- Prior settlement (shares) 4,273,438
- Reported change -1.65%
- Days to cover (reported) 3.47
Reported to FINRA as of the 2026-08-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sanofi (SNY)
- Regeneron Pharmaceuticals (REGN)
- AstraZeneca (AZN)
- GSK (GSK)
- Eli Lilly (LLY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare APGE vs…
APOGEE THERAPEUTICS INC is found in…
Frequently asked questions
What does APOGEE THERAPEUTICS INC (APGE) do?
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologic product candidates for the treatment of inflammatory and immunology conditions. Its development programs target high unmet needs in diseases including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. The company is currently a party to a pending acquisition agreement with AbbVie.
What sector is APOGEE THERAPEUTICS INC (APGE) in?
APOGEE THERAPEUTICS INC (APGE) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are APOGEE THERAPEUTICS INC's (APGE) competitors?
Notable peers of APOGEE THERAPEUTICS INC (APGE) include Sanofi, Regeneron Pharmaceuticals, AstraZeneca, GSK and Eli Lilly. This peer set is informational only — not financial advice.
Where does stocks-llm's data on APGE come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. This listing has ended, so these are the last figures on record rather than current ones — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are the last daily closes recorded before this listing ended.
Last updated 2026-09-04.
Informational only — NOT financial advice. All figures are the last on record before this listing ended, from SEC EDGAR & market data, shown with their as-of date.